Sierra Oncology (SRRA)

Business description

Sierra Oncology is developing new therapies targeting the DNA damage response to treat cancer. It is in Phase I clinical trials of SRA737, an inhibitor of Chk1, both as a monotherapy and in combination with chemotherapy. It is also in IND enabling studies of SRA141, a Cdc7 inhibitor.

Stock data

Market cap.US$165.3m
Last closeUS$3.16
High / Low (52 weeks)US$3.8 / US$1.1
Stock market listingUS
Forecast net cash (US$m)95
Forecast gearing ratio (%)N/A
TeamHealthcare
SectorPharmaceutical & healthcare

Price performance

%1m3m12m
Actual0.673.6125.7
Relative *(3.9)58.682.7

* % Relative to local index

Other companies in sector Show

4SC aap Implantate
Aastrom Biosciences AB Science
Abcam Abivax SA
Ablynx Abzena
Acarix Achillion Pharmaceuticals
Acorda Therapeutics Actinium Pharmaceuticals
Active Biotech Acucela
Addex Therapeutics Adherium
Advanced Medical Solutions Aegerion Pharmaceuticals
Aeterna Zentaris AFT Pharmaceuticals
Agennix Akari Therapeutics
Alchemia Alexza Pharmaceuticals
Algeta Alimera Sciences
ALK Abello Alkermes
Allergy Therapeutics Alliance Pharma
Allium Medical Solutions Alnylam Pharmaceuticals
Amarantus BioScience Amarin
Amplifon AmpliPhi Biosciences
Angle Animalcare Group
Anteo Diagnostics Anthera Pharmaceuticals
Aratana Therapeutics Ardea Biosciences
Ardelyx Arena Pharmaceuticals
arGEN-X Argos Therapeutics
Ariad Pharmaceuticals Arix Bioscience
Ark Therapeutics Group ArQule
Array BioPharma Arrowhead Research Corporation
Ascendis Pharma ASLAN Pharmaceuticals
Astex Pharmaceuticals Athersys
Atossa Genetics Avacta Group
Avalanche Biotechnologies AVEO Pharmaceuticals
Avita Medical Balda
Basilea Pharmaceutica Bavarian Nordic
Bellus Health Benitec Biopharma
BioCryst Pharmaceuticals BioInvent
BioLight Life Sciences BioLineRx
BiondVax Pharmaceuticals Bionomics
Bionor Pharma Biota Holdings
Biotie Therapies Corp Biotron
Bluebird Bio Bone Therapeutics
Bonesupport BrainStorm Cell Therapeutics
BTG C4X Discovery Holdings
Can-Fite BioPharma Capstone Therapeutics
Carmat Cell Therapy
Celldex Therapeutics Cellectis
Cellular Biomedicine Group Celyad
Cerulean Pharma Circadian Technologies
Clal Biotechnology Industries Clavis Pharma
Cleveland BioLabs Clinigen Group
Clinuvel CO.DON
CollPlant Holdings Consort Medical
Corium International Crescendo
Crossject CSL
Curis Cytori Therapeutics
Cytos Biotechnology CytRx Corporation
DBV Technologies Dechra Pharmaceuticals
Delcath Systems Deltex Medical
Derma Sciences DiaSorin
Diaxonhit e-Therapeutics
Egalet Corporation EKF Diagnostics
Elbit Medical Emergent BioSolutions
Endocyte Epigenomics
Erytech Pharma Esperion Therapeutics
Evotec Exact Sciences
Exelixis Factor Therapeutics
Formycon Forward Pharma
Fresenius SE & Co. KGaA Futura Medical
Galapagos Galmed Pharmaceuticals
Genedrive Genfit
Genkyotex Genmab
GeoVax GI Dynamics
Gilead Sciences GNI Group Ltd
GW Pharmaceuticals Halozyme Therapeutics
Heat Biologics Inc. Heidelberg Pharma
Horizon Discovery Hutchison China MediTech
Hybrigenics iCo Therapeutics
Idenix Immune Pharmaceuticals
Immunicum Immunodiagnostic Systems Holdings
Immunovia ImmuPharma
Immutep Imprimis Pharmaceuticals
Imugene Incyte Corporation
Infinity Pharmaceuticals Innate Pharma
Insmed Intec Pharma
International Stem Cell Invion
Ion Beam Applications Ipsogen
Iridex Ironwood Pharmaceuticals
Islet Sciences Ixico
Japan Tobacco KaloBios Pharmaceuticals
Karolinska Development Kazia Therapeutics
Keryx Biopharmaceuticals Kiadis Pharma
Laboratorios Farmacéuticos ROVI LCA-Vision
LeMaitre Vascular Lifeline Scientific
LifeWatch Ligand Pharmaceuticals
Lipocine Lombard Medical Technologies
MagForce Mast Therapeutics
Medcom Tech Medicago
MediciNova Medigene
Medivir Merrimack Pharmaceuticals
Merrion Pharmaceuticals Mesoblast
MethylGene MGC Pharmaceuticals
Midatech Pharma MISSION Therapeutics
Molecular Partners MolMed
Mologen Momenta Pharmaceuticals
MorphoSys Nanobiotix
Nanosonics Navidea Biopharmaceuticals
Nektar Therapeutics NeoStem
Neovacs NetScientific
NeuroVive Pharmaceutical Newron Pharmaceuticals
Nexstim NicOx
NMC Health NorDiag
Nordion NovaBay Pharmaceuticals
Novacyt NPS Pharmaceuticals
Nuevolution Ocata Therapeutics
Omega Diagnostics Group Omeros Corporation
OncoGenex Pharmaceuticals Oncolytics Biotech Inc
OncoMed Pharmaceuticals Onconova Therapeutics
Oncothyreon Onxeo
Onyx Pharmaceuticals Opexa Therapeutics
OPMEDIC Group Optos
Orexigen Therapeutics Orexo
Orgenesis Oryzon Genomics
Ossur OvaScience
Oxford BioMedica Pacific Edge
Paion Paladin Labs
Patheon PDL BioPharma
Pharmacyclics PharmaMar
Pharmaxis Pharming Group
Photocure Phylogica
Pixium Vision Pluristem Therapeutics
Prescient Therapeutics Probiodrug
ProMetic Life Sciences Prosensa
Proteome Sciences PsiOxus
QRxPharma Quantum Genomics
Quantum Pharmaceuticals Race Oncology
RedHill Biopharma Regeneus
Relmada Therapeutics ReNeuron Group
Resverlogix REVA Medical
Rovi RXi Pharmaceuticals
Sangamo BioSciences Sarepta Therapeutics
Sartorius Scancell
Selvita Shire
Silence Therapeutics Simavita
Sinclair Pharma Sirtex Medical
Skyepharma Smith & Nephew
Sobi Sosei Group Corporation
Source Bioscience SQI Diagnostics
Stallergenes StemCells
Stentys Stratec Biomedical
Sucampo Pharmaceuticals Sunesis Pharmaceuticals
Surgical Innovations Sygnis
SymBio Pharmaceuticals Synairgen
Synergy Health Synta Pharmaceuticals
T‐cell cancer therapies Targovax
TearLab Corp Tekmira
TESARO Theraclion
Therapix Biosciences Threshold Pharmaceuticals
ThromboGenics TiGenix
Tissue Regenix Tissue Therapies
Titan Pharmaceuticals Tonix Pharmaceuticals
Topotarget Touchstone Innovations
Transgene Trillium Therapeutics
Trimel Pharmaceuticals TruScreen Ltd
TxCell UCB
UDG Healthcare uniQure NV
Universal Biosensors VBI Vaccines
Vectura Verastem
Verisante Technology Vernalis
Verona Pharma Vertex Pharmaceuticals
Viralytics ViroPharma
Vivalis Vivus
VolitionRx WaferGen Biosystems
Xbrane Biopharma Xencor
Zafgen Zealand Pharma
Ziopharm Oncology

Company news

Sierra Oncology: Significant Potential Upside In 2018

Thu, 26 Oct 2017 12:22:30 GMT

Revisiting The ProNAi/Sierra Oncology Thesis 1 Year Later: Still Not Dead In ...

Mon, 17 Jul 2017 17:37:30 GMT

Buy Sierra Oncology Ahead Of A 2018 Full Of Catalysts

Mon, 23 Oct 2017 15:50:38 GMT

Sierra Oncology to Present at the Biotech Showcase in San Francisco

Wed, 03 Jan 2018 12:00:00 GMT

Sierra Oncology to Present at the Jefferies 2017 London Healthcare Conference

Tue, 07 Nov 2017 12:00:00 GMT

Y/E Dec Revenue (US$m) EBITDA (US$m) PBT (US$m) EPS (fd) (c) P/E (x) P/CF (x)
2015A 0.0 (32.5) (32.6) (226.2) N/A N/A
2016A 0.0 (41.6) (41.4) (136.9) N/A N/A
2017E 0.0 (38.2) (38.1) (76.0) N/A N/A
2018E 0.0 (43.1) (42.8) (76.6) N/A N/A

Last updated on 08/12/2017

Investment summary

Sierra Oncology is a drug developer targeting the DNA damage response (DDR) network to treat cancer. The company has two Phase I trials with SRA737 targeting checkpoint kinase 1 (Chk1) in patients with genetic tumor types expected to respond to the drug. Inhibition of Chk1 is lethal in cells with defective p53 (among others), one of the most common cancer mutations, and may also be potentiated by low-dose chemotherapy. Interim results are expected in early 2018. Sierra also has the cell division cycle 7 (Cdc7) inhibitor SRA141 in preclinical testing.

Last updated on 13/12/2017

Industry outlook

Chk1 inhibition, the mode of action for Sierra's lead compound, has an exceptionally high potential to address multiple cancers of different lineages due to the ubiquity of the mutations it has demonstrated synthetic lethality with.

Last updated on 13/12/2017

Key management

Nick Glover, CEO
Diana Papove, Manager, Corporate Affairs
James Smith, VP Corporate Affairs

Company address

885 West Georgia Street, Suite 2150
Vancouver, British Columbia
V6C 3E8
Canada
View website